Murray Sheldon
Overview
Explore the profile of Murray Sheldon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mao J, Ansari S, Siddiqui A, Sedrakyan A, Marinac-Dabic D, Sheldon M, et al.
J Neurointerv Surg
. 2024 Jun;
PMID: 38862209
Background: Real-world data can be helpful in evaluating endovascular therapy (EVT) in ischemic stroke care. We conducted a pilot study to aggregate data on basilar artery occlusion (BAO) EVT from...
2.
Levin L, Sheldon M, McDonough R, Aronson N, Rovers M, Gibson C, et al.
Int J Technol Assess Health Care
. 2024 Jan;
40(1):e13.
PMID: 38282208
Objectives: Evidence development for medical devices is often focused on satisfying regulatory requirements with the result that health professional and payer expectations may not be met, despite considerable investment in...
3.
Chaudhuri S, Ben Chaouch Z, Hauber B, Mange B, Zhou M, Christopher S, et al.
J Biopharm Stat
. 2023 Mar;
:1-20.
PMID: 36861942
A fixed one-sided significance level of 5% is commonly used to interpret the statistical significance of randomized clinical trial (RCT) outcomes. While it is necessary to reduce the false positive...
4.
Sedrakyan A, Marinac-Dabic D, Campbell B, Aryal S, Baird C, Goodney P, et al.
BMJ Surg Interv Health Technol
. 2022 Nov;
4(Suppl 1):e000123.
PMID: 36393894
Objectives: Generating and using real-world evidence (RWE) is a pragmatic solution for evaluating health technologies. RWE is recognized by regulators, health technology assessors, clinicians, and manufacturers as a valid source...
5.
Leroy H, Gressler L, Liebeskind D, Brooks C, Siddiqui A, Ansari S, et al.
BMJ Surg Interv Health Technol
. 2022 Nov;
4(Suppl 1):e000113.
PMID: 36393891
No abstract available.
6.
Flythe J, Forfang D, Gedney N, White D, Wilkie C, Cavanaugh K, et al.
Kidney360
. 2022 Aug;
3(7):1197-1209.
PMID: 35919522
Background: Recent innovations have the potential to disrupt the current paradigm for kidney failure treatment. The US Food and Drug Administration is committed to incorporating valid scientific evidence about how...
7.
Campbell B, Wilkinson J, Marlow M, Sheldon M
BMJ Surg Interv Health Technol
. 2022 Jan;
1(1):e000022.
PMID: 35047781
No abstract available.
8.
Benz H, Caldwell B, Ruiz J, Saha A, Ho M, Christopher S, et al.
MDM Policy Pract
. 2021 Jul;
6(1):23814683211021380.
PMID: 34277950
A growing literature has developed on identifying outcomes that matter to patients. This study demonstrates an approach involving patient and regulatory perspectives to identify outcomes that are meaningful in the...
9.
10.
Hauber B, Mange B, Zhou M, Chaudhuri S, Benz H, Caldwell B, et al.
MDM Policy Pract
. 2021 Feb;
6(1):2381468320978407.
PMID: 33521289
Parkinson's disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients' preferences for novel neurostimulation devices may help ensure that devices are delivered in a...